Home LiteratureArticle Details
PMID: 2991399 Published · ppublish English Case Reports Journal Article Research Support, U.S. Gov't, P.H.S.

Ca+2 mobilization and fibrinogen binding of platelets refractory to adenosine diphosphate stimulation.

The Journal of laboratory and clinical medicine ·Vol. 106 ·No. 2 ·1985-08-00 ·Pages 111-22

Peerschke EI

Abstract

The mechanism of adenosine diphosphate (ADP)-induced refractoriness was explored with iodine 125-labeled fibrinogen and the fluorescent Ca+2 indicator quin-2-tetraacetoxymethyl ester (quin-2). Gel-filtered platelets were rendered refractory by incubation (30 minutes, 22 degrees C) with either 10 mumol/L ADP alone or ADP and 125I-labeled fibrinogen. During the incubation period, platelets incubated with ADP alone showed an initial increase in quin-2 fluorescence, which gradually returned to baseline levels. Addition of 125I-fibrinogen to aliquots of the platelet suspension at various times during incubation showed that fibrinogen binding was normal after 1 minute but decreased to 50% in 30 minutes. According to Scatchard analysis, this decreased binding was attributed to decreased fibrinogen receptor availability, not decreased receptor affinity. Moreover, similar numbers of glycoprotein (GP) IIb-IIIa complexes remained available on platelets before and after incubation, as judged by the ability of a monoclonal antibody (10E5) directed against a complex specific epitope on GPIIb or IIIa to bind to control and refractory platelets. After incubation, platelets aggregated poorly in response to restimulation with ADP, although the amount of fibrinogen they bound (50% of normal) was sufficient to aggregate control platelets. Platelet restimulation with ADP was not accompanied by a rise in quin-2 fluorescence or exposure of additional fibrinogen receptors. Stimulation of platelets with thrombin, however, led to a rise in quin-2 fluorescence, exposure of additional fibrinogen receptors, and enhanced aggregation. Restimulation of platelets with epinephrine also increased fibrinogen receptor exposure and restored the ability of platelets to aggregate, but was accompanied by barely detectable changes in quin-2 fluorescence similar to those observed with epinephrine-treated control platelets. Platelets incubated for 30 minutes with ADP and 125I-fibrinogen also showed an initial rise in quin-2 fluorescence, which returned to baseline levels during incubation, but the amount of platelet-bound fibrinogen, normal at the onset, remained quantitatively unchanged. Much of this fibrinogen, however, no longer dissociated from platelets in the presence of ethylenediaminetetraacetic acid or apyrase, suggesting that a different type of platelet-fibrinogen interaction had developed. Restimulation of these platelets with ADP was not accompanied by increased fibrinogen binding or quin-2 fluorescence and failed to elicit significant platelet aggregation.(ABSTRACT TRUNCATED AT 400 WORDS)

MeSH Terms
Adenosine Diphosphate/pharmacology Aminoquinolines Antibodies, Monoclonal Blood Platelets/drug effects,metabolism Calcium/blood Fluorescent Dyes Humans Platelet Aggregation/drug effects Platelet Membrane Glycoproteins Receptors, Cell Surface/metabolism Serotonin/blood Spectrometry, Fluorescence Time Factors
Chemicals
Aminoquinolines Antibodies, Monoclonal Fluorescent Dyes Platelet Membrane Glycoproteins Receptors, Cell Surface Serotonin Adenosine Diphosphate Quin2 Calcium
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Peerschke E I
Article Info
Journal
The Journal of laboratory and clinical medicine
Abbr.
J Lab Clin Med
ISSN
0022-2143
Published
1985-08-00
Pages
111-22
Language
English
Region
United States
NLM ID
0375375
Subset
IM
Grants
NHLBI NIH HHS · HL 28183 · United States
External Links
PubMed source
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com